Table 3.
Cox regression analyses
| Patient group | Hazard ratio (95% CI) | P value |
|---|---|---|
| Entire cohort ( n = 5935) | ||
| Age (y) | ||
| <55a | 1.00 | |
| 56–65 | 1.10 (1.01–1.21) | .037 |
| 66–75 | 1.26 (1.16–1.37) | <.001 |
| >75 | 1.48 (1.35–1.64) | <.001 |
| Sex | ||
| Femalea | 1.00 | |
| Male | 1.07 (1.00–1.13) | .035 |
| Node status | ||
| Negativea | 1.00 | |
| Positive | 1.38 (1.30–1.47) | <.001 |
| Tumor size (cm) | ||
| <2a | 1.00 | |
| >2 | 1.37 (1.27–1.48) | <.001 |
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.40 (1.31–1.48) | <.001 |
| Stage I ( n = 845) | ||
| Age (y) | ||
| <55a | 1.00 | |
| 56–65 | 1.21 (.92–1.58) | .18 |
| 66–75 | 1.50 (1.17–1.91) | .001 |
| >75 | 1.72 (1.31–2.26) | <.001 |
| Tumor size (cm) | ||
| <2a | 1.00 | |
| >2 | 1.33 (1.11–1.60) | .002 |
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.28 (1.07–1.54) | .007 |
| Stage IIA ( n = 1501) | ||
| Tumor size (cm) | ||
| <2a | 1.00 | |
| >2 | 1.27 (1.10–1.47) | .001 |
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.43 (1.26–1.61) | <.001 |
| Stage IIB ( n = 3140) | ||
| Age (y) | ||
| <55a | 1.00 | |
| 56–65 | 1.04 (.92–1.17) | .543 |
| 66–75 | 1.23 (1.10–1.38) | <.001 |
| >75 | 1.54 (1.34–1.76) | <.001 |
| Tumor size (cm) | ||
| <2a | 1.00 | |
| >2 | 1.37 (1.23–1.54) | <.001 |
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.38 (1.27–1.50) | <.001 |
| Stage III ( n = 384) | ||
| Age (y) | ||
| <55a | 1.00 | |
| 56–65 | 1.19 (.86–1.64) | .29 |
| 66–75 | 1.37 (1.00–1.86) | .047 |
| >75 | 1.81 (1.28–2.57) | .001 |
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.28 (1.02–1.59) | .032 |
| Stage IV ( n = 270) | ||
| Tumor grade | ||
| Lowa | 1.00 | |
| High | 1.58 (1.21–2.05) | .001 |
n = patients with all variables available for regression analysis
aReferent